Targeting the Highest Value Inflection Points
Clinical Proof of Concept
- Developing innovative treatments for patients & advancing new technology.
- Generating in-human clinical proof of concept data.
- Value creation driven by clinical & regulatory pathways.
- Includes drugs & devices pre-Phase I and pre-Phase II.
- Target exit 5-7 years
Product Launch
- Launching biotech & medtech products targeting patient unmet need.
- Marketing authorization approved or approval within 12-months.
- In-human efficacy data has already been generated.
- Focused on growth of commercial infrastructure.
- Target exit in 3-5 years.
Partners
*
Our Investments
Track Record
Product Launches
in 60 Countries
in 60 Countries
40
Years Experience
100+
Raised
$500M
Exited
$2.7B
If you consider all our roles as company executives & angel investors. All figures are presented gross of any fees & expenses.
How we delivered for patients
Zeneus Pharma
$120M raised - Acquired by Cephalon for $360M
Specialty pharma platform focused on oncology and anti-infectives. Built commercial ops across Europe.
EUSA Pharma I & II
$390M raised - Acquired for $700M & $825M
Developed and commercialized rare disease medicines. Two separate build + exits in less than 10 years.
Aircraft Medical
$10M raised - Acquired by Covidien for $110M
Developed advanced video laryngoscopes for anesthesia and emergency intubation.
Izana Bioscience
$1M + grants - Acquired by Roivant for $42M
Developed namilumab, an anti-GM-CSF monoclonal antibody repurposed for COVID-19 and inflammatory diseases.
